Screener
Theravance Biopharma TBPH Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 416,662 | 418,460 |
| Long-term marketable securities | — | 11,128 |
| Property and equipment, net | 5,169 | 5,895 |
| Operating lease assets | 21,926 | 24,371 |
| Restricted cash | 836 | 836 |
| Other assets | 25,177 | 24,880 |
| Total assets | $469,770 | $485,570 |
| Liabilities and Shareholders' Equity |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's operating lease ROU assets?
- Theravance Biopharma (TBPH) reported operating lease ROU assets of $21.93M in Q2 2026.
- How has Theravance Biopharma's operating lease ROU assets changed year-over-year?
- Theravance Biopharma's operating lease ROU assets decreased by 17.2% year-over-year, from $26.49M to $21.93M.
- What is the long-term trend for Theravance Biopharma's operating lease ROU assets?
- Over 5 years (2020 to 2025), Theravance Biopharma's operating lease ROU assets has grown at a -10.8% compound annual growth rate (CAGR), from $43.26M to $24.37M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Theravance Biopharma's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude